Heidelberg Pharma collaborates and holds license agreements with several leading academic and clinical institutions as well as pharmaceutical companies worldwide. License agreements are an important part of the Company’s commercialization strategy.
The Company uses the ATAC technology to produce candidates for its own development portfolio. Heidelberg Pharma develops these up to early clinical development phases with the aim of demonstrating their applicability and efficacy in patients.
Heidelberg Pharma also licenses its technology platform to other pharmaceutical companies for the development of their own ATACs. The partner provides specific antibodies that are coupled with Amanitin and takes over the entire preclinical and clinical development of these ATACs.
Development partners for the ATAC technology include Takeda as well as the US-American Binghamton University.
Material Supply Model
Heidelberg Pharma works with production partners to supply its license partners with Amanitin linker material in GMP quality for their development projects as needed.
An exclusive multi-target research agreement has been in place with Takeda Pharmaceutical Company Limited since June 2017 for the co-development of ADCs that use Amanitin as payload. Under the terms of the exclusive research agreement, Heidelberg Pharma produced several ATACs using antibodies from Takeda’s proprietary portfolio. In September 2022 Takeda was granted an exclusive license to commercially develop an Antibody Targeted Amanitin Conjugate directed to a previously selected target molecule. Takeda is responsible for further preclinical and clinical development, as well as potential commercialization, of the licensed product candidate.
In December 2022, Heidelberg Pharma signed a research and exclusive option agreement with the US-American Binghamton University, State University of New York, related to a novel and proprietary immunostimulatory technology platform. The platform includes potent novel immunostimulatory compounds and Antibody Drug Conjugate (ADC) technology for the specific delivery of these compounds to tumor tissue. The resulting immunostimulatory ADCs have the potential to harness the patient’s own immune system to attack and eliminate malignancies. These immunostimulatory agents are synergistic with cytotoxic agents, including ADCs generated by Heidelberg Pharma’s ATAC technology. The scientific team at Binghamton University has generated a solid preclinical data package demonstrating potent anti-tumor activity.
TLX250-CDx (INN: 124I-girentuximab) is a radiolabeled form of the monoclonal antibody Girentuximab, which binds to the Carbonic Anhydrase-9 (CAIX) antigen, expressed on the surface of cancer cells of the clear-cell phenotype. It has been shown that TLX250-CDx with positron emission tomography (PET) and computer tomography (CT) is clearly superior to the use of diagnostic CT alone in diagnosing clear cell renal cell carcinomas.
Heidelberg Pharma has entered into a worldwide license agreement for the development and commercialization of TLX250-CDx with the Australian company Telix Pharmaceuticals Limited in January 2017.
upamostat is an inhibitor of the uPA system and, in the Company's view, represents a promising new, non-cytotoxic approach for the specific inhibition of metastasis and primary tumor growth in solid tumors. upamostat was developed by Heidelberg Pharma to Phase II.
Heidelberg Pharma has entered into a licensing and development partnership for upamostat in China with Link Health Group in March 2014.
Interested in our technology?
We are looking for interesting partnerships to work together on the further development of the unique mode of action of the active ingredient Amanitin.
Please contact our Business Development team if you are interested in a collaboration or would like to learn more about our proprietary ATAC technology.
Your contact person
Dr. George Badescu